Symptoms and General Pathology

All Conditions

Skin and Connective Tissue Diseases

Necrosis

Psoriasis

Skin Diseases

Skin Diseases, Papulosquamous

Anti-Inflammatory Agents

All Drugs and Chemicals

Dermatologic Agents

Amino Acids

Tumor Necrosis Factor Inhibitors

Deucravacitinib

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Deucravacitinib 6mg oral intake once daily for 4 weeks

Matching Placebo oral intake once daily for 4 weeks

Franziska Stuber, RN

Curdin Conrad, Professor

Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists.

This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis.

During 4 weeks the patients of the 2 arms receive either Deucravacitinib 6mg 1x/day or an identically looking placebo.

At Week 4, Patients with underlying disease of Crohn's disease, colitis ulcerosa, uveitis will stop the study, to avoid that they are too long without efficient treatment for their underlying disease.

Patients with underlying disease of psoriasis or psoriatic arthritis will have the possiblity to continue in Part 2, where they all will receive Deucravacitinib 6mg 1x/day, open label for 3 months

TYK2 Inhibition in Paradoxical Psoriasis

Tyrosine Kinase 2 (TYK2) Inhibition in Paradoxical Psoriasis A Randomized, Double-blind, Placebo-controlled Multi-center Study Evaluating the Effect of Deucravacitinib on Severity of Psoriasis in Patients With Paradoxical Psoriasis

Normalization of inflammatory gene signature

Percentage of patients attaining PxP IGA 0/1 and at least a reduction of 2 points from baseline

Change of Paradoxical Psoriasis Body Surface Area ( PxP-BSA )

Change of Paradoxical Psoriasis palmoplantar Psoriasis Area and Severity Index (PxP PPPASI) Score in patients presenting paradoxical psoriasis of the hands of feet

Change of Paradoxical Psoriasis Scalp Investigator General Assessment (PxP-scalp IGA) if paradoxical Psoriasis is affecting the Scalp

Change of Psoriasis Area and Severity Index (PASI) in patients with pre-existing disease of Psoriasis

Percentage of patients with underlying disease of psoriasic arthritis, having an American College of Rheumatology (ACR) Score of 20%, 50% or 70% reduction in comparion with the Baseline assessment.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
TYK2 Inhibition in Paradoxical Psoriasis	NCT06281106	Psoriasis	Deucravacitinib	18 Years -	Centre Hospitalier Universitaire Vaudois
TYK2 Inhibition in Paradoxical Psoriasis	NCT06281106	Psoriasis	Deucravacitinib	18 Years -	Centre Hospitalier Universitaire Vaudois

Spots Global Cancer Trial Database for deucravacitinib